NCT02411448 2026-01-16RELAYEli Lilly and CompanyPhase 3 Active not recruiting545 enrolled 24 charts 2 FDA
NCT04145349 2025-12-08CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell TumorEli Lilly and CompanyPhase 1/2 Active not recruiting30 enrolled 16 charts
NCT02711553 2025-08-03A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and CompanyPhase 2 Active not recruiting309 enrolled 22 charts